Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12032-023-01951-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Repeat GammaTile Brachytherapy in the Long-Term Management of Recurrent High-Grade Glioma: A Case Report.
Cureus
December 2024
Neurological Surgery, Upstate University Hospital, Syracuse, USA.
Over the past two decades, despite the emergence of various novel therapies for glioblastoma, patient survival outcomes remain poor, particularly in the recurrent stage of the disease. Cesium-131 (Cs-131) brachytherapy presents a promising treatment option for patients with newly diagnosed and recurrent brain neoplasms, enabling the initiation of radiation therapy at the time of tumor resection. This approach eliminates the typical delay in therapy following surgery and the need for multiple return visits for fractionated external beam radiotherapy.
View Article and Find Full Text PDFSpatially-resolved analyses of muscle invasive bladder cancer microenvironment unveil a distinct fibroblast cluster associated with prognosis.
Front Immunol
December 2024
Institute of Urology and Nephrology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Background: Muscle-invasive bladder cancer (MIBC) is a prevalent cancer characterized by molecular and clinical heterogeneity. Assessing the spatial heterogeneity of the MIBC microenvironment is crucial to understand its clinical significance.
Methods: In this study, we used imaging mass cytometry (IMC) to assess the spatial heterogeneity of MIBC microenvironment across 185 regions of interest in 40 tissue samples.
Design and in silico analysis of a novel peptide-based multiepitope vaccine against glioblastoma multiforme by targeting tumor-associated macrophage.
Heliyon
December 2024
Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
CD204 is a distinct indicator for tumor-associated macrophages (TAMs) in glioma. Evidence indicates that CD204-positive TAMs are involved in the aggressive behavior of various types of cancers. This study was conducted to develop a new and effective peptide-based vaccine for GBM, specifically targeting CD204.
View Article and Find Full Text PDFChlorotoxin-functionalized mesoporous silica nanoparticles for pH-responsive paclitaxel delivery to Glioblastoma multiforme.
Heliyon
January 2025
BioSense Institute, University of Novi Sad, Dr Zorana Djindjica 1, 21000, Novi Sad, Serbia.
Glioblastoma multiforme (GBM) is a highly aggressive brain cancer associated with poor survival rates. We developed novel mesoporous silica nanoparticles (MSNs)-based nanocarriers for pH-responsive delivery of a therapeutic drug Paclitaxel (PTX) to GBM tumor cells. The pores of MSNs are loaded with PTX, which is retained by β-cyclodextrin (CD) moieties covalently linked to the pore entrances through a hydrazone linkage, which is cleavable in weakly acidic environment.
View Article and Find Full Text PDFModern insights of nanotheranostics in the glioblastoma: An updated review.
Biochim Biophys Acta Mol Basis Dis
January 2025
Department of Chemical and Biological Engineering, Gachon University, 1342 Seongnam Daero, Seongnam-Si, Gyeonggi-Do 13120, Republic of Korea. Electronic address:
Glioblastoma multiforme (GBM) is a highly malignant subtype of glioma, originating from the glial cells that provide support to other neurons in the brain. GBM predominantly impacts the cerebral hemisphere of the brain, with minimal effects on the cerebellum, brain stem, or spinal cord. Individuals diagnosed with GBM commonly encounter a range of symptoms, starting from auditory abnormalities to seizures.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!